# ANKTIVA (inbakicept) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/inbakicept

> The PDUFA target action date for ANKTIVA (inbakicept), sponsored by ImmunityBio, Inc. (IBRX), is January 6, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the ANKTIVA (inbakicept) PDUFA date?

The PDUFA target action date for ANKTIVA (inbakicept), sponsored by ImmunityBio, Inc. (IBRX), is January 6, 2027. Status: scheduled. SEC Form 10-Q: "In May 2026, we announced the FDA accepted for review our sBLA for ANKTIVA indicated with BCG for the treatment of adult patients with BCG-unresponsive NMIBC with papillary tumors without CIS and assigned a PDUFA target action date of January 6, 2027." Last confirmed August 4, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/inbakicept)

Source: SEC Form 10-Q, accession 0001326110-26-000079, https://www.sec.gov/Archives/edgar/data/1326110/000132611026000079/ibrx-20260630.htm (retrieved 2026-11-12). Last confirmed 2026-08-04. Cite: https://sec-api.dev/pdufa/inbakicept#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | ANKTIVA (inbakicept) |
| Codes |  |
| Sponsor | ImmunityBio, Inc. (IBRX) https://sec-api.dev/companies/ibrx/catalysts |
| Indications | bcg-naïve nmibc, bgc-unresponsive nonmuscle invasive bladder cancer |
| Modality | fusion_protein |
| FDA designations | accelerated, breakthrough |

## Timeline

### April 22, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2024-11-12, last confirmed 2025-05-12.
- SEC Form 8-K (accession 0001193125-24-274438): "On April 22, 2024, the FDA approved our product, ANKTIVA with bacillus Calmette-Guérin ("BCG") for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer ("NMIBC") with carcinoma in situ ("CIS"), with or without papillary tumors (the "approved product")." https://www.sec.gov/Archives/edgar/data/1326110/000119312524274438/d883742d8k.htm
- SEC Form 10-Q (accession 0001326110-25-000071): "On April 22, 2024, the FDA approved our product ANKTIVA and as a result, on May 13, 2024 Oberland purchased additional Revenue Interests from us for a gross purchase price of $100.0 million, less $3.1 million of issuance costs." https://www.sec.gov/Archives/edgar/data/1326110/000132611025000071/ibrx-20250331.htm
- SEC Form 10-Q (accession 0001326110-25-000071): "We have only one approved product, ANKTIVA, for which we received approval from the FDA on April 22, 2024." https://www.sec.gov/Archives/edgar/data/1326110/000132611025000071/ibrx-20250331.htm
- SEC Form 10-Q (accession 0001326110-25-000071): "On April 22, 2024, the FDA approved our product ANKTIVA and as a result, on May 13, 2024 Oberland purchased additional Revenue Interests from us for a gross purchase price of $100.0 million, less certain issuance costs." https://www.sec.gov/Archives/edgar/data/1326110/000132611025000071/ibrx-20250331.htm
- SEC Form 10-Q (accession 0001326110-25-000071): "On April 22, 2024, the FDA approved ANKTIVA with BCG for the treatment of adult patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors for commercial sale, and we have commenced generating revenue, although we expect it to take some time to generate significant revenue from our approved product." https://www.sec.gov/Archives/edgar/data/1326110/000132611025000071/ibrx-20250331.htm
- SEC Form 10-Q (accession 0001326110-25-000071): "On April 22, 2024, the FDA approved our product, ANKTIVA with BCG for the treatment of adult patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors." https://www.sec.gov/Archives/edgar/data/1326110/000132611025000071/ibrx-20250331.htm
- SEC prospectus (424B) (accession 0001193125-25-075804): "On April 22, 2024, the FDA approved our product, ANKTIVA with BCG for the treatment of adult patients with" https://www.sec.gov/Archives/edgar/data/1326110/000119312525075804/d947103d424b5.htm
- SEC Form 10-K (accession 0001326110-25-000033): "On April 22, 2024, the FDA approved our product, ANKTIVA with BCG for the treatment of adult patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors (the "approved product")." https://www.sec.gov/Archives/edgar/data/1326110/000132611025000033/ibrx-20241231.htm
- SEC Form 10-K (accession 0001326110-25-000033): "On April 22, 2024, the FDA approved our product, ANKTIVA with BCG for the treatment of adult patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors." https://www.sec.gov/Archives/edgar/data/1326110/000132611025000033/ibrx-20241231.htm
- SEC Form 10-K (accession 0001326110-25-000033): "On April 22, 2024, the FDA approved ANKTIVA with BCG for the treatment of adult patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors for commercial sale, and we have commenced generating revenue, although we expect it to take some time to generate significant revenue from our approved product." https://www.sec.gov/Archives/edgar/data/1326110/000132611025000033/ibrx-20241231.htm
- SEC Form 10-K (accession 0001326110-25-000033): "We have only one approved product, ANKTIVA, for which we received approval from the FDA on April 22, 2024." https://www.sec.gov/Archives/edgar/data/1326110/000132611025000033/ibrx-20241231.htm
- SEC Form 10-K (accession 0001326110-25-000033): "On April 22, 2024, the FDA approved our product ANKTIVA and as a result, on May 13, 2024 Oberland purchased additional Revenue Interests from us for a gross purchase price of $100.0 million, less certain issuance costs." https://www.sec.gov/Archives/edgar/data/1326110/000132611025000033/ibrx-20241231.htm

### April 23, 2024: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2025-07-28, last confirmed 2025-07-28.
- SEC prospectus (424B) (accession 0001193125-25-165807): "Although such designations may not lead to a faster development process or regulatory review and may not increase the likelihood that a product candidate will receive approval, N-803 (Anktiva), our lead biologic commercial product candidate, has received Breakthrough Therapy and Fast Track designations and is currently under review by the U.S. Food and Drug Administration (the FDA) for treatment in combination with bacillus Calmette-Guérin (BCG) of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without Ta or T1 disease and has a new user fee goal date (PDUFA date) of April 23, 2024." https://www.sec.gov/Archives/edgar/data/1326110/000119312525165807/d941601d424b5.htm
- SEC Form 8-K (accession 0001193125-24-274438): "On April 22, 2024, the FDA approved our product, ANKTIVA with bacillus Calmette-Guérin ("BCG") for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer ("NMIBC") with carcinoma in situ ("CIS"), with or without papillary tumors (the "approved product")." https://www.sec.gov/Archives/edgar/data/1326110/000119312524274438/d883742d8k.htm

### Mar 2025: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-05-05, last confirmed 2025-05-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-112057): "In March 2025, the Company completed its submission to the FDA of the sBLA for the use of ANKTIVA plus BCG in BCG-unresponsive NMIBC in the papillary indication." https://www.sec.gov/Archives/edgar/data/1326110/000119312525112057/d949868dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-112057): "Relying on this unanimous guidance the Company submitted the sBLA on March 2025." https://www.sec.gov/Archives/edgar/data/1326110/000119312525112057/d949868dex991.htm

### September 26, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-02-23, last confirmed 2026-11-09.
- SEC Form 10-Q (accession 0001326110-26-000099): "After SRS's motion for leave to amend was denied, on September 26, 2025, SRS sent the company a further notice of claims and essentially the same arbitration demand, asserting that the company had breached its obligations to exercise commercially reasonable efforts to achieve FDA approval of ANKTIVA on or before December 31, 2022." https://www.sec.gov/Archives/edgar/data/1326110/000132611026000099/ibrx-20260930.htm
- SEC Form 10-Q (accession 0001326110-26-000079): "After SRS's motion for leave to amend was denied, on September 26, 2025, SRS sent the company a further notice of claims and essentially the same arbitration demand, asserting that the company had breached its obligations to exercise commercially reasonable efforts to achieve FDA approval of ANKTIVA on or before December 31, 2022." https://www.sec.gov/Archives/edgar/data/1326110/000132611026000079/ibrx-20260630.htm
- SEC Form 10-Q (accession 0001326110-26-000059): "After SRS's motion for leave to amend was denied, on September 26, 2025, SRS sent the company a further notice of claims and essentially the same arbitration demand, asserting that the company had breached its obligations to exercise commercially reasonable efforts to achieve FDA approval of ANKTIVA on or before December 31, 2022." https://www.sec.gov/Archives/edgar/data/1326110/000132611026000059/ibrx-20260331.htm
- SEC Form 10-K (accession 0001326110-26-000030): "After SRS's motion for leave to amend was denied, on September 26, 2025, SRS sent the company a further notice of claims and essentially the same arbitration demand, asserting that the company had breached its obligations to exercise commercially reasonable efforts to achieve FDA approval of ANKTIVA on or before December 31, 2022." https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231.htm

### Q4 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter. Indication: BCG-naïve NMIBC.
- First seen 2026-11-09, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001326110-26-000091): "the planned submission of a supplemental Biologics License Application (sBLA) for ANKTIVA® (nogapendekin alfa inbakicept-pmln) to the FDA by year-end 2026 and the timing and outcome of the FDA's review thereof" https://www.sec.gov/Archives/edgar/data/1326110/000132611026000091/ibrx-20261198xkexhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001326110-26-000097): "•BCG Naïve Primary Endpoint Met: In November 2026, we reported that the primary endpoint for Cohort A was met in the randomized QUILT-2.005 trial, and we remain on track to submit an sBLA to the FDA in the fourth quarter of 2026 for ANKTIVA in combination with BCG in patients with BCG-naïve NMIBC." https://www.sec.gov/Archives/edgar/data/1326110/000132611026000097/ibrx-2026119x8kexhibit991.htm

### October 14, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact. Indication: BGC-unresponsive nonmuscle invasive bladder cancer.
- First seen 2026-11-09, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001326110-26-000097): "•FDA Expanded Approval: On October 14, 2026, the U.S. Food and Drug Administration (FDA) approved our supplemental Biologics License Application (sBLA) expanding the approved indication for ANKTIVA® in combination with Bacillus Calmette-Guérin (BCG) to include adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)." https://www.sec.gov/Archives/edgar/data/1326110/000132611026000097/ibrx-2026119x8kexhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001326110-26-000097): "In this quarter (October 2026), ImmunityBio received FDA approval for expanded use of ANKTIVA plus BCG in subjects with BGC-unresponsive nonmuscle invasive bladder cancer (NMIBC)." https://www.sec.gov/Archives/edgar/data/1326110/000132611026000097/ibrx-2026119x8kexhibit991.htm
- SEC Form 10-Q (accession 0001326110-26-000099): "On October 14, 2026, the FDA approved our sBLA expanding the approved indication for ANKTIVA in combination with BCG to include adult patients with BCG-unresponsive NMIBC." https://www.sec.gov/Archives/edgar/data/1326110/000132611026000099/ibrx-20260930.htm
- SEC Form 10-Q (accession 0001326110-26-000099): "•On October 14, 2026, the FDA approved our sBLA expanding the approved indication for ANKTIVA in combination with BCG to include adult patients with BCG-unresponsive NMIBC." https://www.sec.gov/Archives/edgar/data/1326110/000132611026000099/ibrx-20260930.htm

### January 6, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-08-04, last confirmed 2026-08-04.
- SEC Form 10-Q (accession 0001326110-26-000079): "In May 2026, we announced the FDA accepted for review our sBLA for ANKTIVA indicated with BCG for the treatment of adult patients with BCG-unresponsive NMIBC with papillary tumors without CIS and assigned a PDUFA target action date of January 6, 2027." https://www.sec.gov/Archives/edgar/data/1326110/000132611026000079/ibrx-20260630.htm
- SEC Form 10-Q (accession 0001326110-26-000079): "•The FDA accepted for review the company's sBLA for ANKTIVA indicated with BCG in patients with BCG-unresponsive NMIBC with papillary tumors without CIS and assigned a PDUFA target action date of January 6, 2027" https://www.sec.gov/Archives/edgar/data/1326110/000132611026000079/ibrx-20260630.htm
- SEC Form 10-Q (accession 0001326110-26-000079): "In May 2026, we announced that the FDA had accepted for review the sBLA for ANKTIVA indicated with BCG for the treatment of adult patients with BCG-unresponsive NMIBC with papillary disease without CIS and assigned a PDUFA target action date of January 6, 2027." https://www.sec.gov/Archives/edgar/data/1326110/000132611026000079/ibrx-20260630.htm

Calendar months: [January 2027](https://sec-api.dev/fda-calendar/2027-01)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/inbakicept.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ANKTIVA (inbakicept) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/inbakicept

```bibtex
@misc{secapidev_pdufa_inbakicept_20261116,
  title        = {ANKTIVA (inbakicept) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/inbakicept}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_inbakicept_20261116","title":"ANKTIVA (inbakicept) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/inbakicept","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
